Biotech · Private company
Talaris Therapeutics Inc.
Track this companyFree. Adds Talaris Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials110 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- FCR001Phase 3 · Transplanted Organ RejectionClinicalTrials.gov · fetched Nov 12, 2026
- Enriched Hematopoetic Stem Cell InfusionPhase 2 · Anemia, Sickle CellClinicalTrials.gov · fetched Nov 12, 2026
- Enriched Hematopoetic Stem Cell InfusionPhase 2 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Enriched Hematopoietic Stem Cell InfusionPhase 2 · Kidney FailureClinicalTrials.gov · fetched Nov 12, 2026
- Enriched Hematopoietic Stem Cell InfusionPhase 2 · Renal FailureClinicalTrials.gov · fetched Nov 12, 2026
- FCR001Phase 2 · Kidney TransplantationClinicalTrials.gov · fetched Nov 12, 2026
- FCR001Phase 2 · Diffuse Cutaneous Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- hematopoietic stem cell infusionPhase 2 · Hurler Syndrome (MPS I)ClinicalTrials.gov · fetched Nov 12, 2026
- Biological/Vaccine: Enriched Hematopoetic Stem Cell InfusionRenal FailureClinicalTrials.gov · fetched Nov 12, 2026
- Enriched Hematopoetic Stem Cell InfusionMetachromatic LeukodystrophyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic SclerosisPHASE1_PHASE2 · WITHDRAWN · started Nov 24, 2021ClinicalTrials.gov NCT05098145 · fetched Nov 12, 2026
- A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney TransplantationPHASE3 · TERMINATED · started Oct 25, 2019ClinicalTrials.gov NCT03995901 · fetched Nov 12, 2026
- A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney RecipientsPHASE2 · WITHDRAWN · started Oct 15, 2012ClinicalTrials.gov NCT01649388 · fetched Nov 12, 2026
- Phase I/II Pilot Study of Mixed Chimerism to Treat HemoglobinopathiesPHASE1_PHASE2 · WITHDRAWN · started May 1, 2011ClinicalTrials.gov NCT01419704 · fetched Nov 12, 2026
- Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic DisordersPHASE1_PHASE2 · TERMINATED · started Apr 1, 2011ClinicalTrials.gov NCT01372228 · fetched Nov 12, 2026
- Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx InfusionPHASE2 · TERMINATED · started Mar 1, 2008ClinicalTrials.gov NCT00497926 · fetched Nov 12, 2026
- Phase I/II Pilot Study of Mixed Chimerism to Treat HemoglobinopathiesPHASE1_PHASE2 · COMPLETED · started Jan 1, 2005ClinicalTrials.gov NCT00777231 · fetched Nov 12, 2026
- Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell InfusionPHASE1_PHASE2 · UNKNOWN · started Jan 1, 2005ClinicalTrials.gov NCT00498160 · fetched Nov 12, 2026
- Single Patient Expanded Access Protocol: Metabolic BoostNO_LONGER_AVAILABLEClinicalTrials.gov NCT02021266 · fetched Nov 12, 2026
- Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)NO_LONGER_AVAILABLEClinicalTrials.gov NCT02051673 · fetched Nov 12, 2026
- Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)NO_LONGER_AVAILABLEClinicalTrials.gov NCT02084121 · fetched Nov 12, 2026